101. Trends in disease-modifying therapy use in patients with multiple sclerosis using a 10-year population-based cohort study in France
- Author
-
Soline Leblanc, Mathilde Lefort, Emmanuelle Le Page, Laure Michel, Emmanuelle Leray, Centre de Recherches sur l'Action Politique en Europe (ARENES), Université de Rennes (UR)-Institut d'Études Politiques [IEP] - Rennes-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Centre National de la Recherche Scientifique (CNRS), CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), École des Hautes Études en Santé Publique [EHESP] (EHESP), Département Méthodes quantitatives en santé publique (METIS), Collectif de recherche handicap, autonomie et société inclusive (CoRHASI), This work was supported by 'Institut des Neurosciences Cliniques de Rennes', France., and EHESP, SCD
- Subjects
Cohort Studies ,Multiple sclerosis ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,untreated ,General Neuroscience ,Humans ,Pharmacology (medical) ,Disease-modifying therapies ,Health administrative database ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Neurology (clinical) ,France ,Time-series - Abstract
International audience; Background: The availability of new disease-modifying therapies (DMTs) for patients with multiple sclerosis (MS) provides an opportunity for improving outcomes but makes disease management more complex. Our study aimed to describe changes in therapeutic practices over the period 2009-2018 and measure the impact of the arrival of oral DMTs on the use of injectable DMTs.Methods: Data were extracted from a representative 1/97 sample of the French population covered by the healthcare insurance system. Study period was set from 1 January 2009 to 31 December 2018. Four periods of MS identification were defined (before 2009, 2009-2011, 2012-2015 and 2016-2018).Results: Overall, 1,508 patients with MS were included, of whom 876 (58.1%) were treated at least once over the study period. Untreated patients were older and had more comorbidities than treated ones. First-line DMTs were the most frequent initial DMT (78.5%) and a shift has operated from injectable to oral drugs over time. The proportion of patients receiving several DMTs increased with the number of available drugs. End 2018, beta interferon, glatiramer acetate, teriflunomide, dimethylfumarate, fingolimod and natalizumab shared nearly equal parts.Conclusions: This study provides valuable insights into the real-world use of DMTs and changes that have operated over time.
- Published
- 2022
- Full Text
- View/download PDF